BioRegenx, Inc. entered into a letter of intent to acquire Findit, Inc. (OTCPK:FDIT) from WooEB, Inc., Hva Family Trust and others in a reverse merger transaction on January 7, 2022. BioRegenx, Inc. entered into a definitive agreement to acquire Findit, Inc. from WooEB, Inc. and others in a reverse merger transaction on December 29, 2022. Findit will issue to BioRegenx, not more than 337,793,959 shares of Common Stock, and 836,048 Series A preferred shares representing approximately 90% of the Company?s outstanding voting securities. Pursuant to the Definitive Agreement, BioRegenx shall be merged into Findit and all of the issued and outstanding BioRegenx common and preferred shares shall be exchanged for common and preferred shares of Findit. Findit shall issue common and preferred shares in an amount equivalent to 90.0% of the voting securities of Findit. Concurrently, holder(s) of Findit Series A and Series B preferred shares shall retire their Series A and Series B preferred shares back into the treasury. The Series A and Series B preferred shares to be retired represent a voting control of 98.47% of Findit. The exchange value of Finditstock would be the average closing price of Findit for the month of November 2022. As soon as practical after the merger, both parties agree to the implementation of up to a 1 for 25 reverse split of Findit's common and preferred stock. The merger will constitute a major change of control of the public entity to the executive team of BioRegenx. The various functions of Findit.com will continue as usual and one of the core members of the Findit executive team will continue on the board of the merged entity. The name of the public entity will be changed to BioRegenx, Inc. As of January 17, 2024, the merger of BioRegenx, Inc. into Atlanta GA/Findit, Inc. (OTC PINK:FDIT) was cleared by the SEC.

The transaction is subject to customary closing conditions including regulatory approvals, Resignation of Officers and Directors of Findit, the approval of BioRegenx shareholders, the approval of the Findit's shareholders, all of the current assets and liabilities of FDIT, shall be transferred into a wholly owned subsidiary, the Principals of FDIT shall execute an option agreement with FDIT relating to its acquisition of all of their shares in Classworx (CHNO), subsequent to the merger and Retirement of Series A and Series B preferred shares. Transaction has been approved by each company's board of directors. Findit Board unanimously approved the Merger Agreement. Findit stockholder approval was obtained effective December 29, 2022. The transaction is anticipated to close in the first quarter of 2023. As of January 3, 2024, the transaction is expected to be complete before the end of the first quarter of 2024. Clear Trust, LLC acted as transfer agent and registrar to Findit.

BioRegenx, Inc. completed the acquisition of Findit, Inc. (OTCPK:FDIT) from WooEB, Inc., Hva Family Trust and others in a reverse merger transaction on March 8, 2024.